An update on adjuvant systemic therapies in melanoma

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2019-11-01 DOI:10.2217/mmt-2019-0009

E. Samuel, M. Moore, M. Voskoboynik, M. Shackleton, A. Haydon

引用次数: 11

Abstract

There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize treatment strategies in all stages of the disease to provide better patient outcomes. The role of adjuvant therapy in patients with resected stage 3 melanoma is a rapidly evolving field. Interferon was the first agent shown to have any utility in this space, however, recent advances in both targeted therapies and immunotherapies have led to a number of practice changing adjuvant trials in resected stage 3 disease.

查看原文本刊更多论文

黑色素瘤辅助系统治疗的最新进展

根据国际癌症研究机构的统计数据，全球黑色素瘤的发病率正在上升，2018年全球约有30万例新病例。随着发病率的上升，在疾病的各个阶段优化治疗策略以提供更好的患者预后是很重要的。辅助治疗在切除的3期黑色素瘤患者中的作用是一个快速发展的领域。干扰素是第一个在这一领域显示出效用的药物，然而，靶向治疗和免疫治疗的最新进展已经导致了一些在切除的3期疾病中改变实践的辅助试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.